EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C18H13ClFN3 |
| Net Charge | 0 |
| Average Mass | 325.774 |
| Monoisotopic Mass | 325.07820 |
| SMILES | Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2 |
| InChI | InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3 |
| InChIKey | DDLIGBOFAVUZHB-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antitubercular agent A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis. GABAA receptor agonist A GABA receptor agonist specific for GABAA receptors, ligand-gated ion channels (also known as ionotropic receptors). antiviral agent A substance that destroys or inhibits replication of viruses. antifungal agent An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. anti-HBV agent An antiviral agent that destroys or inhibits the replication of the hepatitis B virus. anti-HIV agent An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. anti-obesity agent Any substance which is used to reduce or control weight. antimalarial A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. apoptosis inducer Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. GABA modulator A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. |
| Applications: | antidepressant Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. antitussive An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. anticonvulsant A drug used to prevent seizures or reduce their severity. antiinfective agent A substance used in the prophylaxis or therapy of infectious diseases. anti-anaemic agent A compound which increases either the number of red cells or the amount of haemoglobin in the blood. central nervous system depressant A loosely defined group of drugs that tend to reduce the activity of the central nervous system. antiatherosclerotic agent A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antitubercular agent A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis. muscle relaxant A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis. GABAA receptor agonist A GABA receptor agonist specific for GABAA receptors, ligand-gated ion channels (also known as ionotropic receptors). ophthalmology drug Any compound used for the treatment of eye conditions or eye diseases. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. antipsychotic agent Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. general anaesthetic Substance that produces loss of consciousness. hepatoprotective agent Any compound that is able to prevent damage to the liver. antiparkinson drug A drug used in the treatment of Parkinson's disease. antidote Any protective agent counteracting or neutralizing the action of poisons. vulnerary A drug used in treating and healing of wounds. antirheumatic drug A drug used to treat rheumatoid arthritis. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. anti-inflammatory agent Any compound that has anti-inflammatory effects. dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. antiemetic A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors. bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. antimalarial A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. hypoglycemic agent A drug which lowers the blood glucose level. antipsoriatic A drug used to treat psoriasis. anxiolytic drug Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. sedative A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. GABA modulator A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| midazolam (CHEBI:6931) has role analgesic (CHEBI:35480) |
| midazolam (CHEBI:6931) has role anti-anaemic agent (CHEBI:75835) |
| midazolam (CHEBI:6931) has role anti-HBV agent (CHEBI:64951) |
| midazolam (CHEBI:6931) has role anti-HIV agent (CHEBI:64946) |
| midazolam (CHEBI:6931) has role anti-inflammatory agent (CHEBI:67079) |
| midazolam (CHEBI:6931) has role anti-obesity agent (CHEBI:74518) |
| midazolam (CHEBI:6931) has role antiatherosclerotic agent (CHEBI:145947) |
| midazolam (CHEBI:6931) has role anticonvulsant (CHEBI:35623) |
| midazolam (CHEBI:6931) has role antidepressant (CHEBI:35469) |
| midazolam (CHEBI:6931) has role antidote (CHEBI:50247) |
| midazolam (CHEBI:6931) has role antiemetic (CHEBI:50919) |
| midazolam (CHEBI:6931) has role antifungal agent (CHEBI:35718) |
| midazolam (CHEBI:6931) has role antihypertensive agent (CHEBI:35674) |
| midazolam (CHEBI:6931) has role antiinfective agent (CHEBI:35441) |
| midazolam (CHEBI:6931) has role antimalarial (CHEBI:38068) |
| midazolam (CHEBI:6931) has role antineoplastic agent (CHEBI:35610) |
| midazolam (CHEBI:6931) has role antiparkinson drug (CHEBI:48407) |
| midazolam (CHEBI:6931) has role antipsoriatic (CHEBI:50748) |
| midazolam (CHEBI:6931) has role antipsychotic agent (CHEBI:35476) |
| midazolam (CHEBI:6931) has role antirheumatic drug (CHEBI:35842) |
| midazolam (CHEBI:6931) has role antitubercular agent (CHEBI:33231) |
| midazolam (CHEBI:6931) has role antitussive (CHEBI:51177) |
| midazolam (CHEBI:6931) has role antiviral agent (CHEBI:22587) |
| midazolam (CHEBI:6931) has role anxiolytic drug (CHEBI:35474) |
| midazolam (CHEBI:6931) has role apoptosis inducer (CHEBI:68495) |
| midazolam (CHEBI:6931) has role bone density conservation agent (CHEBI:50646) |
| midazolam (CHEBI:6931) has role cardiovascular drug (CHEBI:35554) |
| midazolam (CHEBI:6931) has role central nervous system depressant (CHEBI:35488) |
| midazolam (CHEBI:6931) has role dermatologic drug (CHEBI:50177) |
| midazolam (CHEBI:6931) has role GABAA receptor agonist (CHEBI:91016) |
| midazolam (CHEBI:6931) has role general anaesthetic (CHEBI:38869) |
| midazolam (CHEBI:6931) has role hepatoprotective agent (CHEBI:62868) |
| midazolam (CHEBI:6931) has role hypoglycemic agent (CHEBI:35526) |
| midazolam (CHEBI:6931) has role immunosuppressive agent (CHEBI:35705) |
| midazolam (CHEBI:6931) has role muscle relaxant (CHEBI:51371) |
| midazolam (CHEBI:6931) has role neuroprotective agent (CHEBI:63726) |
| midazolam (CHEBI:6931) has role ophthalmology drug (CHEBI:66981) |
| midazolam (CHEBI:6931) has role sedative (CHEBI:35717) |
| midazolam (CHEBI:6931) has role vulnerary (CHEBI:73336) |
| midazolam (CHEBI:6931) is a benzodiazepine (CHEBI:22720) |
| midazolam (CHEBI:6931) is a imidazobenzodiazepine (CHEBI:142118) |
| midazolam (CHEBI:6931) is a monofluorobenzenes (CHEBI:83575) |
| midazolam (CHEBI:6931) is a organic molecular entity (CHEBI:50860) |
| midazolam (CHEBI:6931) is a organochlorine compound (CHEBI:36683) |
| Incoming Relation(s) |
| 1-hydroxymidazolam (CHEBI:145330) has functional parent midazolam (CHEBI:6931) |
| 1',4-dihydroxymidazolam (CHEBI:145332) has functional parent midazolam (CHEBI:6931) |
| 4-hydroxymidazolam (CHEBI:145331) has functional parent midazolam (CHEBI:6931) |
| midazolam hydrochloride (CHEBI:6932) has part midazolam (CHEBI:6931) |
| IUPAC Name |
|---|
| 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine |
| INNs | Source |
|---|---|
| midazolam | WHO MedNet |
| midazolam | WHO MedNet |
| midazolam | WHO MedNet |
| midazolamum | WHO MedNet |
| Synonyms | Source |
|---|---|
| mezolam | DrugCentral |
| Midazolam civ | ChEMBL |
| USL-261 | ChEMBL |
| USL261 | ChEMBL |
| Brand Names | Source |
|---|---|
| Buccolam | KEGG DRUG |
| Dormicum | KEGG DRUG |
| Midazolam in 0.8% sodium chloride | ChEMBL |
| Midazolam in 0.9% sodium chloride | ChEMBL |
| Nayzilam | ChEMBL |
| Registry Numbers | Sources |
|---|---|
| Reaxys:625572 | Reaxys |
| CAS:59467-70-8 | ChemIDplus |
| CAS:59467-70-8 | NIST Chemistry WebBook |
| CAS:59467-70-8 | KEGG COMPOUND |
| Citations |
|---|